The evolving understanding of microRNA in bladder cancer

Elizabeth A. Guancial, Joaquim Bellmunt, Shuyuan Yeh, Jonathan E. Rosenberg, David M. Berman

Research output: Contribution to journalArticle

Abstract

Purpose: Micro ribonucleic acid (miR) expression is altered in urologic malignancies, including bladder cancer (BC). Individual miRs have been shown to modulate multiple signaling pathways that contribute to BC. We reviewed the primary literature on the role of miRs in BC; we provide a general introduction to the processing, regulation, and function of miRs as tumor suppressors and oncogenes and critically evaluate the literature on the implications of altered miR expression in BC. Materials and methods: We searched the English language literature for original and review articles in PubMed from 1993 to March 2013, using the terms "microRNA" and "bladder cancer," "transitional cell carcinoma," or "urothelial carcinoma." This search yielded 133 unique articles with more than 85% of them published within the last 3 years. Results: To date, the majority of miR studies in BC use profiling to describe dynamic changes in miR expression across stage and grade. Generalized down-regulation of miRs, including those that target the fibroblast growth factor 3 pathway, such as miR-145, miR-101, miR-100, and miR-99a, has been observed in low-grade, non-muscle invasive BC. In contrast, generalized increased expression of miRs is observed in high-grade, muscle-invasive BC compared with adjacent normal bladder urothelium, including miRs predicted to target p53, such as miR-21 and miR-373. Furthermore, p53 suppresses transcriptional factors that promote mesenchymal differentiation, ZEB-1 and ZEB-2, through regulation of the miR200 family. Conclusions: Aberrations in miR expression identified between non-muscle invasive BC and muscle-invasive BC provide insight into the molecular alterations known to distinguish the two parallel pathways of bladder carcinogenesis. The heterogeneity of tumor specimens and research methods limits the reproducibility of changes in miR expression profiles between studies and underscores the importance of in vivo validation in a field that utilizes in silico miR target-prediction models.

Original languageEnglish (US)
JournalUrologic Oncology: Seminars and Original Investigations
Volume32
Issue number1
DOIs
StatePublished - Jan 2014
Externally publishedYes

Fingerprint

MicroRNAs
Urinary Bladder Neoplasms
RNA
Fibroblast Growth Factor 3
Urinary Bladder
Muscle Neoplasms
Urothelium
Neoplasms
Transitional Cell Carcinoma
Oncogenes
PubMed
Computer Simulation
Carcinogenesis
Language
Down-Regulation
Carcinoma

Keywords

  • Biomarkers
  • MicroRNAs
  • Urinary bladder neoplasm

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

The evolving understanding of microRNA in bladder cancer. / Guancial, Elizabeth A.; Bellmunt, Joaquim; Yeh, Shuyuan; Rosenberg, Jonathan E.; Berman, David M.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 32, No. 1, 01.2014.

Research output: Contribution to journalArticle

Guancial, Elizabeth A. ; Bellmunt, Joaquim ; Yeh, Shuyuan ; Rosenberg, Jonathan E. ; Berman, David M. / The evolving understanding of microRNA in bladder cancer. In: Urologic Oncology: Seminars and Original Investigations. 2014 ; Vol. 32, No. 1.
@article{08bf42f668a44254a612e758100c46d7,
title = "The evolving understanding of microRNA in bladder cancer",
abstract = "Purpose: Micro ribonucleic acid (miR) expression is altered in urologic malignancies, including bladder cancer (BC). Individual miRs have been shown to modulate multiple signaling pathways that contribute to BC. We reviewed the primary literature on the role of miRs in BC; we provide a general introduction to the processing, regulation, and function of miRs as tumor suppressors and oncogenes and critically evaluate the literature on the implications of altered miR expression in BC. Materials and methods: We searched the English language literature for original and review articles in PubMed from 1993 to March 2013, using the terms {"}microRNA{"} and {"}bladder cancer,{"} {"}transitional cell carcinoma,{"} or {"}urothelial carcinoma.{"} This search yielded 133 unique articles with more than 85{\%} of them published within the last 3 years. Results: To date, the majority of miR studies in BC use profiling to describe dynamic changes in miR expression across stage and grade. Generalized down-regulation of miRs, including those that target the fibroblast growth factor 3 pathway, such as miR-145, miR-101, miR-100, and miR-99a, has been observed in low-grade, non-muscle invasive BC. In contrast, generalized increased expression of miRs is observed in high-grade, muscle-invasive BC compared with adjacent normal bladder urothelium, including miRs predicted to target p53, such as miR-21 and miR-373. Furthermore, p53 suppresses transcriptional factors that promote mesenchymal differentiation, ZEB-1 and ZEB-2, through regulation of the miR200 family. Conclusions: Aberrations in miR expression identified between non-muscle invasive BC and muscle-invasive BC provide insight into the molecular alterations known to distinguish the two parallel pathways of bladder carcinogenesis. The heterogeneity of tumor specimens and research methods limits the reproducibility of changes in miR expression profiles between studies and underscores the importance of in vivo validation in a field that utilizes in silico miR target-prediction models.",
keywords = "Biomarkers, MicroRNAs, Urinary bladder neoplasm",
author = "Guancial, {Elizabeth A.} and Joaquim Bellmunt and Shuyuan Yeh and Rosenberg, {Jonathan E.} and Berman, {David M.}",
year = "2014",
month = "1",
doi = "10.1016/j.urolonc.2013.04.014",
language = "English (US)",
volume = "32",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - The evolving understanding of microRNA in bladder cancer

AU - Guancial, Elizabeth A.

AU - Bellmunt, Joaquim

AU - Yeh, Shuyuan

AU - Rosenberg, Jonathan E.

AU - Berman, David M.

PY - 2014/1

Y1 - 2014/1

N2 - Purpose: Micro ribonucleic acid (miR) expression is altered in urologic malignancies, including bladder cancer (BC). Individual miRs have been shown to modulate multiple signaling pathways that contribute to BC. We reviewed the primary literature on the role of miRs in BC; we provide a general introduction to the processing, regulation, and function of miRs as tumor suppressors and oncogenes and critically evaluate the literature on the implications of altered miR expression in BC. Materials and methods: We searched the English language literature for original and review articles in PubMed from 1993 to March 2013, using the terms "microRNA" and "bladder cancer," "transitional cell carcinoma," or "urothelial carcinoma." This search yielded 133 unique articles with more than 85% of them published within the last 3 years. Results: To date, the majority of miR studies in BC use profiling to describe dynamic changes in miR expression across stage and grade. Generalized down-regulation of miRs, including those that target the fibroblast growth factor 3 pathway, such as miR-145, miR-101, miR-100, and miR-99a, has been observed in low-grade, non-muscle invasive BC. In contrast, generalized increased expression of miRs is observed in high-grade, muscle-invasive BC compared with adjacent normal bladder urothelium, including miRs predicted to target p53, such as miR-21 and miR-373. Furthermore, p53 suppresses transcriptional factors that promote mesenchymal differentiation, ZEB-1 and ZEB-2, through regulation of the miR200 family. Conclusions: Aberrations in miR expression identified between non-muscle invasive BC and muscle-invasive BC provide insight into the molecular alterations known to distinguish the two parallel pathways of bladder carcinogenesis. The heterogeneity of tumor specimens and research methods limits the reproducibility of changes in miR expression profiles between studies and underscores the importance of in vivo validation in a field that utilizes in silico miR target-prediction models.

AB - Purpose: Micro ribonucleic acid (miR) expression is altered in urologic malignancies, including bladder cancer (BC). Individual miRs have been shown to modulate multiple signaling pathways that contribute to BC. We reviewed the primary literature on the role of miRs in BC; we provide a general introduction to the processing, regulation, and function of miRs as tumor suppressors and oncogenes and critically evaluate the literature on the implications of altered miR expression in BC. Materials and methods: We searched the English language literature for original and review articles in PubMed from 1993 to March 2013, using the terms "microRNA" and "bladder cancer," "transitional cell carcinoma," or "urothelial carcinoma." This search yielded 133 unique articles with more than 85% of them published within the last 3 years. Results: To date, the majority of miR studies in BC use profiling to describe dynamic changes in miR expression across stage and grade. Generalized down-regulation of miRs, including those that target the fibroblast growth factor 3 pathway, such as miR-145, miR-101, miR-100, and miR-99a, has been observed in low-grade, non-muscle invasive BC. In contrast, generalized increased expression of miRs is observed in high-grade, muscle-invasive BC compared with adjacent normal bladder urothelium, including miRs predicted to target p53, such as miR-21 and miR-373. Furthermore, p53 suppresses transcriptional factors that promote mesenchymal differentiation, ZEB-1 and ZEB-2, through regulation of the miR200 family. Conclusions: Aberrations in miR expression identified between non-muscle invasive BC and muscle-invasive BC provide insight into the molecular alterations known to distinguish the two parallel pathways of bladder carcinogenesis. The heterogeneity of tumor specimens and research methods limits the reproducibility of changes in miR expression profiles between studies and underscores the importance of in vivo validation in a field that utilizes in silico miR target-prediction models.

KW - Biomarkers

KW - MicroRNAs

KW - Urinary bladder neoplasm

UR - http://www.scopus.com/inward/record.url?scp=84890788122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890788122&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2013.04.014

DO - 10.1016/j.urolonc.2013.04.014

M3 - Article

C2 - 23911686

AN - SCOPUS:84890788122

VL - 32

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 1

ER -